Discovering targeted
medicines
Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis
Drug discovery with a strong track record
Exceptional capabilities in medicinal chemistry and translational science are the foundation of Redx. We have built an attractive portfolio of assets and have a strong track record of drug discovery. Our drug discovery engine has delivered five molecules to clinical stage development, and we have completed a number of major partnering transactions in recent years. Our portfolio includes two Phase 2 assets; RXC004, a Porcupine inhibitor targeting Wnt-ligand dependent tumours and RXC007, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis, as well as a pipeline of rapidly advancing research programs and collaborations, driven by our world-class drug discovery engine.
Our Pipeline
Target/Product
Indications
Research
Preclinical
Phase 1
Phase 2
Phase 3
Upcoming Milestones
Topline data – from H1 2023
Genetically selected pancreatic cancer monotherapy Biliary cancer monotherapy + anti-PD-1 combination
ROCK2 Selective Inhibitor
(RXC007)
Idiopathic pulmonary fibrosis (IPF)
Phase 2a topline data – H2 2023
GI-targeted ROCK Inhibitor
(RXC008)
Fibrostenotic Crohn’s Disease
IND/CTA submission – end 2023
DDR Inhibitor
(Discoidin Domain Receptor)
Fibrosis, Cancer-associated fibrosis
Progress programmes – target of 2 IND’s by 2025
Research Targets
(Wholly-owned)
Oncology & Fibrosis
Porcupine Inhibitor
(RXC006/AZD5055)
Idiopathic pulmonary fibrosis (IPF)
Licensed to AstraZeneca
MAPK Pathway
Target
Oncology
Progress Jazz Collaboration
DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase
Our Pipeline
UPCOMING MILESTONES
Topline data – from H1 2023
UPCOMING MILESTONES
Phase 2a topline data – H2 2023
UPCOMING MILESTONES
IND/CTA submission – end 2023
UPCOMING MILESTONES
Progress programmes – target of 2 IND’s by 2025
Research Targets
(Wholly-owned)
UPCOMING MILESTONES
Licensed to AstraZeneca
UPCOMING MILESTONES
Sold to Jazz Pharmaceuticals
MAPK Pathway
Target
UPCOMING MILESTONES
Progress Jazz Collaboration
DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase
Latest news
-
23-Jan-2023
Redx to Present at the 2nd Annual Wnt & β-Catenin Pathway Targeted Drug Development Summit -
20-Dec-2022
Final Audited Results for the Year Ended 30 September 2022 -
16-Dec-2022
Redx Signs Clinical Trial Collaboration and Supply Agreement with MSD to evaluate RXC004 in combination with KEYTRUDA® (pembrolizumab) in PORCUPINE2 Study in Biliary Cancer
Our values
At Redx, our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster.
Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need.
Underpinning our work are our five core company values that underline in everything we do:

High Standards
We stand or fall by quality data

Agility
The market waits for no-one

Innovation
Bright ideas fuel our pipeline

Resilience
We can’t win by giving up

Teamwork
Together we are stronger
